Supernus Pharmaceuticals (SUPN) Shares Outstanding (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Shares Outstanding (Entity) of $58.2 million for Q2 2026, up 3.64% year-over-year from $56.1 million in Q2 2025, and little changed on a QoQ basis from $58.0 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Shares Outstanding (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Shares Outstanding (Entity) for 16 years, with the latest figure at $58.2 million in Q2 2026.
- Shares Outstanding (Entity) for Q2 2026 came in at $58.2 million, up 3.64% year-over-year; the trailing twelve-month figure through Jun 2026 was $58.2 million (up 3.64% YoY), and the FY2025 annual result was $57.5 million, up 3.08% from the prior year.
- Shares Outstanding (Entity) held at $58.2 million in Q2 2026, from $58.0 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $58.2 million in Q2 2026 and troughed at $53.4 million in Q1 2022.
- A 5-year average of $55.4 million and a median of $55.0 million in 2023 frame the typical range for Shares Outstanding (Entity).
- The widest annual swing landed in 2022, when Shares Outstanding (Entity) gained 0.65%; it then climbed 3.66% in 2026.
- A 5-year view of Shares Outstanding (Entity) shows it stood at $54.5 million in 2022, then grew by 0.91% to $55.0 million in 2023, then gained by 1.42% to $55.7 million in 2024, then rose by 3.08% to $57.5 million in 2025, then advanced by 1.23% to $58.2 million in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $58.2 million in Q2 2026, $58.0 million in Q1 2026, and $57.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 832.44 Mn |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | 58.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.07 Mn |
| Mar 31, 2026 | 57.65 Mn |
| Dec 31, 2025 | 56.45 Mn |
| Sep 30, 2025 | 56.55 Mn |
| Jun 30, 2025 | 56.02 Mn |
| Mar 31, 2025 | 55.86 Mn |
| Dec 31, 2024 | 55.10 Mn |
| Sep 30, 2024 | 55.15 Mn |
| Jun 30, 2024 | 54.98 Mn |
| Mar 31, 2024 | 54.80 Mn |
| Dec 31, 2023 | 54.54 Mn |
| Sep 30, 2023 | 54.61 Mn |
| Jun 30, 2023 | 54.50 Mn |
| Mar 31, 2023 | 54.38 Mn |
| Dec 31, 2022 | 53.67 Mn |
| Sep 30, 2022 | 53.79 Mn |
| Jun 30, 2022 | 53.43 Mn |
| Mar 31, 2022 | 53.33 Mn |
| Dec 31, 2021 | 53.10 Mn |
| Sep 30, 2021 | 53.19 Mn |